{"id":"W4286509886","doi":"10.1016/j.jhepr.2022.100544","title":"Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis","year":2022,"lang":"en","type":"article","venue":"JHEP Reports","topic":"Liver Diseases and Immunity","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Toronto Liver Centre; University of Alberta","funders":"Novartis Institutes for BioMedical Research; Intercept Pharmaceuticals; Medical Research Council; Merck; Dr. Falk Pharma; GlaxoSmithKline; National Institute for Health and Care Research; Novartis; Pfizer","keywords":"Ursodeoxycholic acid; Tolerability; Placebo; Medicine; Discontinuation; Internal medicine; Obeticholic acid; Adverse effect; Cholestasis; Gastroenterology; Primary biliary cirrhosis; Farnesoid X receptor; Agonist; Receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004790401,0.0001859379,0.000519611,0.0002211876,0.0001297818,0.00002678661,0.00008989145,0.00004981964,0.0006000871],"category_scores_gemma":[0.0001928474,0.00015386,0.0001402446,0.0004255048,0.00005996891,0.0001381238,0.0001270904,0.0004014871,0.000005070293],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004378217,"about_ca_system_score_gemma":0.0003457559,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006654139,"about_ca_topic_score_gemma":0.00001993771,"domain_scores_codex":[0.9979305,0.0002076513,0.0006452354,0.0004143232,0.0005094057,0.000292914],"domain_scores_gemma":[0.9989038,0.00006462092,0.0002785569,0.0005614689,0.00006139994,0.0001301778],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1135438,0.002207998,0.8766891,0.00006161934,0.00005482269,0.0008377964,0.0002692688,0.000009400431,0.00008936555,6.292311e-7,0.001254911,0.004981298],"study_design_scores_gemma":[0.1759717,0.0009431426,0.8179778,0.00006290279,0.00007107262,0.00004174867,0.0001435641,0.000003648808,0.0000418011,0.000009080381,0.004564781,0.000168753],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956701,0.0002428957,5.295302e-7,0.0002910425,0.0003783993,0.002334283,0.00004947192,0.00004293363,0.0009903072],"genre_scores_gemma":[0.9975192,0.00002767309,0.00006956212,0.0004060085,0.00009253238,0.0005416234,0.0008575208,0.00003495947,0.0004509274],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06242792,"threshold_uncertainty_score":0.6570534,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00779975170173277,"score_gpt":0.2178358120458716,"score_spread":0.2100360603441388,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}